National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) HTA ID: 22022.

Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) in combination with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This Rapid Review assessment pertains to the subpopulation of patients aged 6 to 11 years with cystic fibrosis and who are heterozygous for the F508del mutation and either a minimal function (MF) mutation, or an unknown mutation in the CFTR gene.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/04/2022
Rapid review completed 10/05/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivacaftor/tezacaftor/elexacaftor (Kaftrio®) with a regimen of ivacaftor (Kalydeco®) compared with the current standard of care.